The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Advancing ADC therapy
Valentina Boni, MD, PhD, University Hospital Quironsalud Madrid, Madrid, Spain, discusses the importance of discovering new targets for advancing antibody-drug conjugate (ADC) therapy. Dr Boni highlights the recent changes in the landscape of ADCs following the approval of trastuzumab deruxtecan (TDM-1) for breast cancer, including the development of ASC targeting novel targets such as Claudin-2, MET and B7-H3. These ADCs utilize innovative payloads and aim to address new indications including small cell lung cancer (SCLC), colorectal cancer, and gastric cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
